Diabetes research and clinical practice · 2025
Trends of lower-limb complications in patients with type 2 diabetes mellitus during the COVID-19 pandemic.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luu Ivan Y, Hong Alexander T, Lin Forest, Shin Laura, Shih Chia-Ding, Han Sukgu M, Armstrong David G, Tan Tze-Woei
Аннотация
AIMS: The long-term impact of the COVID-19 pandemic on lower limb complications remains unclear. We aimed to assess the effect of the COVID-19 pandemic on the prevalence of diabetic foot ulcers (DFUs) and the incidence of lower extremity amputation (LEA) in patients with type 2 diabetes.
METHODS: We conducted a cross-sectional analysis using TriNetX and included adults with type 2 diabetes from 2016 to 2023. DFU prevalence and LEA incidence were analyzed across pre-pandemic, pandemic, and post-pandemic periods. Annual percent changes (APC) were calculated using Joinpoint regression.
RESULTS: Among 5,292,512 patients with type 2 diabetes (mean age, 66 ± 14.0 years; 47.3 % female), DFU prevalence increased pre-pandemic (APC 9.08%; 95% CI 6.24, 12.65), remained stable during the pandemic (APC -0.15%; 95% CI -1.94, 1.69), and rose significantly post-pandemic (APC 6.89%; 95% CI 3.50, 9.75). LEA incidence showed similar trends, which increased pre-pandemic (APC 9.18%; 95% CI 7.15, 12.58), remained stable during the pandemic (APC -3.75%; 95% CI -6.45, 0.63), and significantly increased post-pandemic (APC 11.46%; 95% CI 8.09, 19.63).
CONCLUSIONS: The disproportionately sharper increase in LEA rates compared with DFU prevalence post-pandemic suggests that delayed care during the pandemic may have contributed to a higher burden of preventable amputations.
METHODS: We conducted a cross-sectional analysis using TriNetX and included adults with type 2 diabetes from 2016 to 2023. DFU prevalence and LEA incidence were analyzed across pre-pandemic, pandemic, and post-pandemic periods. Annual percent changes (APC) were calculated using Joinpoint regression.
RESULTS: Among 5,292,512 patients with type 2 diabetes (mean age, 66 ± 14.0 years; 47.3 % female), DFU prevalence increased pre-pandemic (APC 9.08%; 95% CI 6.24, 12.65), remained stable during the pandemic (APC -0.15%; 95% CI -1.94, 1.69), and rose significantly post-pandemic (APC 6.89%; 95% CI 3.50, 9.75). LEA incidence showed similar trends, which increased pre-pandemic (APC 9.18%; 95% CI 7.15, 12.58), remained stable during the pandemic (APC -3.75%; 95% CI -6.45, 0.63), and significantly increased post-pandemic (APC 11.46%; 95% CI 8.09, 19.63).
CONCLUSIONS: The disproportionately sharper increase in LEA rates compared with DFU prevalence post-pandemic suggests that delayed care during the pandemic may have contributed to a higher burden of preventable amputations.